Bayer stock trades steady as investors weigh Crop Science headwinds and pharma pipeline
Published on 07/19/2026 at 20:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer stock, representing the German life-sciences group Bayer AG (ISIN DE000BAY0017), continues to mirror a mix of legal risk and operational restructuring in Crop Science alongside long term upside from its pharmaceuticals portfolio. Recent published figures for fiscal 2024 show lower earnings compared with the previous year as the company absorbs litigation costs and restructures its agricultural business, while maintaining significant research spending on new drugs in cardiovascular disease and oncology according to Bayer disclosure for fiscal 2024.
EBITDA near EUR 9 billion in 2024
According to Bayer’s fiscal 2024 reporting, group sales stood at around EUR 47 billion in 2024, compared with approximately EUR 50 billion in 2023 as adverse pricing and volume trends in Crop Science offset growth in pharmaceuticals and consumer health. The company reported EBITDA before special items of roughly EUR 9 billion for 2024, down from around EUR 11 billion in 2023, reflecting weaker agricultural markets and ongoing costs linked to legacy litigation. Net income attributable to shareholders was materially lower than in the prior year, with Bayer signaling the impact of one off charges related to legal provisions and restructuring measures.
Bayer’s Crop Science division generated sales in the region of EUR 22 billion in 2024, versus roughly EUR 24 billion in 2023, as lower herbicide prices and competitive pressure weighed on the business. The division’s EBITDA before special items declined to about EUR 5 billion from around EUR 6 billion a year earlier, underlining the sensitivity of results to glyphosate pricing and farmers’ purchasing behavior. By contrast, the Pharmaceuticals segment reported sales of approximately EUR 18 billion in 2024, slightly above the previous year’s level of around EUR 17 billion, supported by continued demand for the anticoagulant Xarelto and the eye drug Eylea along with initial contributions from newer therapies.
Revenue down year on year, guidance trimmed
Bayer’s fiscal 2024 results show that total revenue declined by roughly 6% compared with 2023, a move that prompted the group to adjust its medium term expectations for certain Crop Science markets. Management reiterated a focus on cost savings and portfolio pruning, with a targeted efficiency program meant to deliver recurring cost reductions in the hundreds of millions of euros per year once fully implemented. At the same time, Bayer continued to invest a significant amount in research and development; R&D spending was in the region of EUR 6 billion in 2024 across the group, including more than EUR 4 billion directed to pharmaceuticals pipeline projects such as anticoagulant successors to Xarelto and heart failure therapies.
In its outlook commentary for fiscal 2025, Bayer indicated that it expects group sales in a corridor around the mid EUR 40 billion level, assuming stable currency conditions and a gradual recovery in agricultural demand. The company’s guidance for EBITDA before special items points to a band modestly above the 2024 figure, contingent on successful execution of restructuring and continued growth in pharmaceuticals. For investors, the quantified comparison between the 2023 and 2024 results underscores how much the Crop Science downturn has compressed overall profitability, even as the pharma and consumer health businesses grow or hold steady.
Further background on Bayer
Investors who want to follow Bayer’s restructuring path and litigation developments can find additional financial details and strategy commentary in the company’s investor materials.
Pharma pipeline around Xarelto and Eylea
Bayer’s Pharmaceuticals division remains a core driver for the group’s long term value. In its 2024 figures, the company highlighted that Xarelto, the oral anticoagulant developed with partner Janssen, generated several billion euros of sales, though facing generic pressure in some markets toward the end of its lifecycle. Eylea, used to treat age related macular degeneration and other retinal conditions, contributed a substantial revenue base, which Bayer aims to defend through next generation ophthalmology treatments. Newer products, including therapies in cardiovascular and oncology, collectively added hundreds of millions of euros in sales, indicating a growing contribution from the innovation pipeline.
The company’s R&D strategy emphasizes precision medicine and targeted therapies. Bayer reported that it is advancing clinical trials for novel heart failure drugs and new oncology compounds, with several phase II and phase III programs underway by 2024. This investment is significant given the scale of group R&D spending, with the pharmaceuticals unit capturing the majority of the EUR 6 billion group R&D budget in 2024. For investors who focus on the drug pipeline, the number that matters is the shift from established cash generators like Xarelto to emerging compounds that can sustain or grow revenue once current blockbusters lose exclusivity.
Crop Science litigation and restructuring
Bayer’s Crop Science division continues to be shaped by the legacy of the Monsanto acquisition and related glyphosate litigation. In its 2024 accounts, the company booked provisions and legal expenses that together amount to several billion euros, depressing net income and affecting cash flow. Bayer has outlined an approach that combines ongoing settlement activity with a legal strategy aimed at limiting future exposure. These measures sit alongside operational changes such as portfolio optimization, including divestments of non core assets and a sharper focus on key crops and technologies.
Operationally, the Crop Science business faces cyclical and structural headwinds. Lower herbicide prices relative to the peak years prior to 2023 have reduced margins, while certain markets have seen farmers delay purchases or switch products. Bayer’s response includes concentrating on higher value seeds and traits, as well as digital farming tools designed to improve yields and resource efficiency. The goal is to move the division toward a more resilient earnings profile by 2025 and beyond, although the 2024 numbers show the scale of the adjustment, with revenue and EBITDA before special items both down compared with 2023.
Consumer Health stable with mid single digit growth
In contrast to the more volatile Crop Science and the R&D heavy pharmaceuticals segment, Bayer’s Consumer Health unit provides a relatively stable contribution. The company’s 2024 figures indicate that Consumer Health sales reached several billion euros, up by a mid single digit percentage compared with 2023. Growth was driven by demand for over the counter products in pain relief, allergy, and nutritional supplements, including brands such as Aspirin, Claritin, and Elevit. Margins in Consumer Health remained comparatively healthy, supported by brand strength and pricing actions that offset input cost inflation.
Bayer emphasizes that the consumer portfolio fits with its overall life sciences positioning, offering self care solutions that sit alongside prescription drugs and agricultural products. For valuation, the Consumer Health division may not move the needle as much as Crop Science or pharmaceuticals, but the steady mid single digit sales growth and solid profitability help underpin group cash flows during periods of volatility in other segments.
Cardiovascular and oncology product focus
Bayer’s wider product strategy increasingly revolves around two key therapeutic areas in its pharmaceuticals pipeline: cardiovascular disease and oncology. In cardiovascular, the company is pursuing successors to Xarelto that can address unmet needs in thrombosis and heart failure with improved safety and efficacy profiles. Clinical stage assets in this area are expected to build on the proven demand for oral anticoagulants and heart failure therapies, where global markets are worth tens of billions of euros per year.
In oncology, Bayer is investing in targeted therapies and immuno oncology combinations. Pipeline assets include drugs aimed at specific genetic mutations or cancer pathways, reflecting a move toward precision medicine. These programs require significant R&D spending and carry inherent risk, but successful late stage candidates can have a transformative impact on the pharmaceuticals revenue trajectory. As of 2024, Bayer’s pipeline documentation shows multiple oncology compounds in mid to late stage development, pointing to potential launches later in the decade if trials deliver positive results and regulators approve the therapies.
Stock reflects mixed segment contributions
Bayer stock performance over the past year reflects the interplay between these segment dynamics. With Crop Science revenue and EBITDA before special items down between 2023 and 2024, investors have discounted some of the agricultural business value due to litigation and market factors. At the same time, the pharmaceuticals and Consumer Health segments continue to generate cash and offer growth potential, particularly through the pipeline’s cardiovascular and oncology focus and the stable mid single digit expansion of consumer products.
When investors analyze Bayer, they must weigh the numbers across divisions: roughly EUR 22 billion in 2024 Crop Science sales versus EUR 18 billion in pharmaceuticals and several billion in Consumer Health, alongside group EBITDA before special items of about EUR 9 billion in 2024 compared with around EUR 11 billion in 2023. These comparative figures illustrate how the group’s earnings profile has shifted, with the litigation burden and agricultural cycle currently overshadowing the steady pharma and consumer contributions. Over time, the significance of the drug pipeline and restructuring outcomes will determine whether Bayer stock can command a higher valuation multiple.
Shares and market context
Bayer shares are listed on Xetra in euros, and the company is a constituent of the DAX index, reflecting its size and importance in the German equity market. The group’s market capitalization amounts to tens of billions of euros, underpinned by its diversified operations across pharmaceuticals, Crop Science, and Consumer Health. The share price has historically been sensitive to news about glyphosate litigation and major pipeline developments, with investors reacting to court rulings, settlement announcements, and clinical trial data.
In the broader sector context, Bayer competes with other global crop science and pharmaceutical companies, and investors often compare its valuation multiples and growth metrics to peers when assessing relative attractiveness. The quantified changes in revenue and EBITDA between 2023 and 2024, along with the guidance for fiscal 2025, give a numerical framework for those comparisons even as legal uncertainties and scientific outcomes remain difficult to predict.
Bayer identity and market data
- Company: Bayer AG
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: XETRA: BAYN
- Trading venue: Xetra
- Price (as of 19 July 2026, 18:00 CET): 29.50 EUR
- Market capitalization: 28.0 billion EUR (as of 19 July 2026)
- Sector / Industry: Health Care / Pharmaceuticals & Life Sciences
- Index membership: DAX
- Next earnings date: 8 August 2026
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
